CardioNXT Raises $2.1M For Atrial Fibrillation Led By Industry Veterans Bullock and Hawkins

CardioNXT is building technologies that enable a better understanding of complex cardiac arrhythmias such as Atrial Fibrillation, and accurately deliver targeted therapy to ectopic source areas within the heart.  The technologies are designed to fit seamlessly into catheter ablation procedural workflow and reduce the cost of procedures.  This attention to cost reduction will not only benefit the U.S. market, it will enable arrhythmia therapies to be adopted rapidly in global markets including underserved emerging markets.

"What appeals to me about this technology is its grass-roots clinical support from very experienced cardiac electrophysiologists," Bullock stated in prepared remarks.  "I believe this is because the technology has the potential to truly improve outcomes in the treatment of Atrial Fibrillation while seamlessly fitting into intraoperative clinical workflow."

"Atrial Fibrillation is a huge problem globally.  This technology has the potential to improve outcomes and make therapy available to patients globally," stated Hawkins.

"Persistent Atrial Fibrillation still remains a very challenging problem for us to treat.  We are quite excited about the potential of this technology to fit into our standard catheter ablation workflow and we look forward to performing the RADAR clinical study, which we now have FDA IDE approval for," stated Vivek Reddy, MD, Director of Cardiac Arrhythmia Service at Mount Sinai Hospital in New York, NY.

Contact:
Kirk Mackin, Business Development Manager
[email protected]
720-381-1690

SOURCE CardioNXT